Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series

Bronchiectasis is a chronic and often progressive disease, which frequently is associated with significant symptom burden requiring intensive treatment. Regardless of the multiple potentially underlying etiologies the vicious cycle of airway inflammation, structural airway damage, impaired mucus clearance and airway pathogen acquisition is the crucial pathogenic pathway for the progression of disease [1]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Rademacher reports grants and personal fees from Bayer Health care, grants and personal fees from Insmed, grants and personal fees from Grifols, personal fees from MSD Sharp & Dohme, personal fees from Astra Zeneca, personal fees from Chiesi, outside the submitted work. Conflict of interest: Dr. Konwert has nothing to disclose. Conflict of interest: Dr. Fuge has nothing to disclose. Conflict of interest: Dr. Dettmer has nothing to disclose. Conflict of interest: Dr. Welte reports personal fees from AstraZeneca, GSK, Grifols, Insmed, Bayer, Novartis, during the conduct of the study; personal fees from Boehringer, Pfizer, outside the submitted work. Conflict of interest: Dr. Ringshausen reports grants, personal fees and other from Bayer Health care, grants, personal fees and other from Insmed Germany, grants and personal fees from Grifols, personal fees from MSD Sharp & Dohme, personal fees from Astra Zeneca, personal fees and other from Chiesi, other from Abbott, personal fees and other from Gilead, other from Pfizer, other from Oxycare, grants, personal fees and other from Novartis, other from Heinen& Lowenstein, other from MSD, grants and other from InfectoPharm, other from Vertex, other from Parion , other from Cetaxsys, other from Corbus, other from GSK, grants from Polyphor, personal fees from Boehringer Ingelheim, other from PARI, other from APOSAN, other from Zambon, other from Heinen+Lowenstein, personal fees from Vortex, outside the submitted work.